Replies to post #99041 on Biotech Values

[drbio45]

Roche's Avastin Should Lose Breast Cancer Approval 12-1



when the panel members called me for my advice on the subject I just pointed them to my earlier post.


Mature survival data showed a HR of 1.103 (95% CI 0.84, 1.45) favoring the placebo arm over the 7.5mg/kg bevacizumab arm. The HR for overall survival was 1.003 (95% CI 0.76, 1.32) for the 15 mg/kg bevacizumab arm compared to the placebo arm

I say approval in this indication should be withdrawn. Society shouldn't have to pay more money for a drug, in this indication, where the person doesn't live longer and has to be sent to the hospital to be treated for severe side effect of the drug.